The $2.2 Billion Neuroscience Mega-Deal Officially Ends After Five Years

Global pharmaceutical giant GSK and biotech company Alector have officially concluded their $2.2 billion central nervous system (CNS) drug co-development partnership, which was initially established in 2021. According to Alector's filing with the U.S. Securities and Exchange Commission (SEC), GSK formally notified Alector of its intent to terminate the collaboration on July 6, 2026, with a 180-day notice period, resulting in the final termination of the agreement on January 2, 2027. As a result of this termination, Alector will regain full rights to the development of its key clinical-stage assets. However, the potential for up to $1.5 billion in development, regulatory, and commercial milestone payments has been completely eliminated.

Consecutive Clinical Failures of Key Candidates Led to the Termination of the Partnership

The primary reason for the dissolution of this alliance is the underperformance of two monoclonal antibody candidates in clinical trials. Latuzinemab (AL001), developed as a treatment for frontotemporal dementia (FTD), failed to achieve its primary endpoint in the Phase 3 (INFRONT-3) trial in October 2025, as it did not demonstrate a statistically significant slowing of disease progression. Subsequently, in April 2026, Nivisnebart (AL101), which was being developed for Alzheimer's disease, received a futility assessment during an interim analysis of its Phase 2 trial, leading to the early termination of its development.

The Survival of the Progranulin Mechanism and the Progress of Competing Pipelines Should Be Monitored

Both drugs utilize an innovative mechanism that blocks the Sortilin receptor in the brain, thereby increasing levels of progranulin (PGRN) protein and contributing to the protection and survival of neurons. However, the consecutive clinical failures have raised serious doubts about the therapeutic efficacy of directly supplementing PGRN levels, similar to Eli Lilly's previous decision to discontinue the development of LY3884963, a gene therapy with a similar mechanism. Currently, the competing pipelines for this mechanism include DNL593 (PTV:PGRN) from Denali Therapeutics, which is pursuing an independent strategy after the termination of its collaboration with Takeda, and PBFT02 from Passage Bio. The future clinical data from these companies will determine the viability of this mechanism.

GSK's Ambitions to Re-enter the Neuroscience Field Have Been Hampered

GSK, which invested a substantial $700 million in upfront payments in an attempt to make a significant re-entry into the field of neurological diseases, has suffered a significant financial loss. GSK had been aggressively pursuing the expansion of its CNS pipeline to diversify its revenue streams, which are currently heavily reliant on oncology and infectious diseases. However, the termination of this partnership has made it necessary to adjust and reorganize its mid- to long-term pipeline strategy. Ultimately, the failure of this potentially multi-billion dollar deal serves as a reminder that the development of CNS treatments remains a high-risk area, even for large pharmaceutical companies.